Reply  by Angiolillo, Dominick J. et al.
Platelet Dysfunction
Associated With Insulin
Therapy in Patients
With Type 2 Diabetes:
Please Do Not Throw the
Baby Out With the Bathwater!
We read with interest the study by Angiolillo et al. (1) demon-
strating that patients with type 2 diabetes have increased platelet
aggregation on dual aspirin–clopidogrel therapy and that patients
with insulin-treated diabetes mellitus (ITDM) have greater aden-
osine diphosphate (ADP)-induced platelet aggregation compared
with patients with non–insulin-treated diabetes mellitus (NITDM)
(1). This is an important observation as 42% of 15,603 randomized
patients (in the CHARISMA [Clopidogrel for High Athero-
thrombotic Risk and Ischemic Stabilization, Management, and
Avoidance] trial) had diabetes (17% treated with insulin), with no
significant better cardiovascular protection of the clopidogrel plus
aspirin combination versus aspirin alone (2). However, Angiolillo
et al.’s (1) finding and interpretation might be considered by
cardiologists as a counterproductive effect of insulin therapy and
represent an erroneous argument for not switching to insulin those
numerous type 2 diabetic patients with poor glucose control while
on oral treatment.
Type 2 diabetes is a progressive disease. Even if it is true that
patients with ITDM are at a more advanced stage of their
metabolic disorder, the need to switch to insulin reflects profound
insulin secretory defect rather than more severe insulin resistance
(3,4), as erroneously stated by Angiolillo et al. (1). That the higher
proportion of women among ITDM subjects may be considered as
an argument supporting the insulin-resistance hypothesis should
also be challenged, as greater insulin resistance in women than in
men is not a classical finding if appropriately measured (5).
Besides glucose-lowering therapy, the most important clinically
relevant difference between the 2 groups was the 1% difference in
hemoglobin A1c (HbA1c) level (7.9% in ITDM patients vs. 6.9%
in those with NITDM, p  0.001), that is, the same difference as
that reported in the intensive group versus the conventional group
in the United Kingdom Prospective Diabetes Study (6). Angiolillo
et al. (1) suggested that this 1% difference could not explain the
difference in platelet reactivity as HbA1c levels were not correlated
with any of the platelet-function assays performed. This finding is in
contrast to other observations showing a significant influence of
glucose levels on platelet reactivity and effect of antiplatelet agents (7).
According to Angiolillo et al. (1), the study was conducted in a tightly
controlled diabetic population, which led to a limited variability in
HbA1c levels; however, the reported 6% coefficient of variation of
HbA1c levels looks astonishingly low with regard to the mean 
SD data of the 2 subgroups (7.9  1.5% vs. 6.9  1.0%).
A key message from the study by Angiolillo et al. (1) is that
aggressive and/or tailored antithrombotic regimens for high-risk
patients such as diabetic patients may be warranted. However,
emphasizing in the “therapeutic implications” section that “treat-
ment with insulin is typically considered a surrogate of increased
atherothrombotic risk” may be misleading. Although this remains
a controversial issue, numerous data do not support this statement
(8). As diabetologists, the key objective is to obtain adequate
metabolic control (HbA1c 7% and ideally 6.0%), in combina-
tion with aggressive management of all other cardiovascular risk
factors, including effective antiplatelet therapy (9). In numerous
patients, insulin therapy is a necessary and often irreplaceable
partner to tackle hyperglycemia and reach HbA1c targets. Please do
not throw the baby out with the bathwater!
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Reply
We appreciate the comments raised by Drs. Scheen and Legrand.
In their letter, they reveal a status of “apprehension” toward the
potential impact of our study (1) on how clinicians may approach
glucose-control management, in particular, avoiding switching to
insulin in patients not well controlled on oral glucose-lowering
medication. Recognizing the importance of the concerns raised
regarding the potential unintended effects of our investigation (1)
this was neither the intent nor the correct interpretation of our
findings.
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Insulin-treated diabetes mellitus (ITDM) patients are at a more
advanced stage of their metabolic disorder, which implies biolog-
ical differences with patients with non-ITDM. In type 2 diabetes
mellitus (T2DM), insulin resistance is a pivotal component of the
metabolic disorder, which increases over time. We agree with Drs.
Scheen and Legrand that progression of the disease may include a
deficiency in insulin secretion, and consequently may lead patients
to require exogenous insulin therapy (2). However, this does not
invalidate our findings. In fact, it is well established that patients
with a longer history of T2DM—thus at an advanced stage of
insulin resistance—are more prone to have less optimal glycemic
control on oral medication and to require exogenous insulin
therapy. Scheen et al. disagree with our interpretation regarding
the prevalence of female subjects in the ITDM group. Although
evaluation of this aspect was not within our study objectives, we
provide recent and robust literature to explain our study findings.
Drs. Scheen and Legrand also raise concerns regarding the
impact of hemoglobin A1c (HbA1c) levels on platelet reactivity.
We would like to rectify that in our study, the coefficient of
variation of HbA1c levels in our T2DM study population was
16%, and not 6%, which is still narrow overall (3), especially
when compared to the broad variability of platelet-function mea-
sures. Although we recognize that glucose control plays a pivotal
role on platelet reactivity, no correlation between the two variables
was observed in our study. This finding supports the hypothesis
that there may be more explicit biological differences between ITDM
and non-ITDM. Although our results (1) differ from the findings of
Watala et al. (4), profound differences exist between the 2 studies.
These differences include number of patients, type of antiplatelet
treatment, degree of glycemic control, and platelet-function assays
used.
Our study is the largest platelet-function analysis performed in
T2DM on sustained dual antiplatelet therapy (1). Most studies
assessing platelet function in T2DM do not describe differences
between ITDM and non-ITDM or they fail to find any difference
due to limited patient sample sizes (5). This can result in failure to
appreciate the biological factors contributing to the less favorable
prognosis in ITDM and may also explain why many clinicians
incorrectly consider insulin treatment per se a “surrogate” of
increased atherothrombotic risk. Our study demonstrates that
biological differences exist between the subgroups of patients with
T2DM. Indeed, we agree with Drs. Scheen and Legrand that the
biological effects of insulin remain controversial (6). However,
ITDM represents among the highest risk of patients for recurrence
of atherothrombotic events.
“Do not throw the baby out with the bathwater”? Indeed, as
cardiologists, we also concur that insulin therapy is necessary and
often irreplaceable to optimally treat hyperglycemia in T2DM.
Nevertheless, this should not hinder our efforts to proactively
investigate alternative factors that contribute to the enhanced
atherothrombotic risk and that affect T2DM, and it is important
that we continue to explore more aggressive and/or customized
antithrombotic treatment regimens in these high-risk patients (7).
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